Shortlist

2026-08-09 17:01 yfinance 216 of 235 usable 12 candidates 216 searchable

Each card shows what you stand to gain and what you stand to lose, computed the same way. Up is the sector median multiple; down is the cheapest quintile, or a 25% fall in EBIT, whichever is worse. The ratio between them is the shape of the arithmetic — it is not odds, and nothing here estimates a probability. The band rates the evidence, not the investment. "Strong case" means most of what can be measured checks out — it does not mean buy, and nothing here knows your portfolio, your horizon or why the market is discounting the company. Red flags outweigh a high count. Read the filings before you act on any row.

No purchase price, no date, no share count — this is an assessment of the company right now, not of your position. Your list is stored on this device only.

Order

Sorted by gap size. The gap is the distance to the sector median multiple, not expected return — and the widest gaps are usually the ones the market has the best reason for. This order puts the most heavily discounted names first, which is also where value traps live. The evidence order exists because of that.

PYPL NASDAQ
PayPal Holdings, Inc.
Financial Services
Price
59.07 USD
P/E
9.7
EV/EBIT
7.4
Worst fall
87.3%
Volatility
38.6%
Below high
80.7%
+38% / -25% 1.5:1

Up: at the Financial Services median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 10/12

Most of what can be measured checks out

Fallen, business intactCheap and healthy
The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 7.4 against a Financial Services median of 8.0 — 6% below peers. Free cash flow yield 11.1%. Trading 81% below its all-time high set 2021-07-23.

Size of the gap

At the Financial Services median EV/EBIT of 8.0 instead of its current 7.4, and with earnings unchanged, the equity would be worth about 7% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 28% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 9/9 — accounts improving year on year
  • revenue compounding at 6% over three years
  • net debt -0.1x EBITDA — balance sheet not forcing anything
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus hold from 33 analysts, mean target 58.83 USD, 0% below the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 189% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Trading 0% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
ADBE NASDAQ
Adobe Inc.
Technology
Price
265.21 USD
P/E
14.8
EV/EBIT
11.7
Worst fall
79.9%
Volatility
48.0%
Below high
61.5%

No two-sided case — see the bet below.

What you'd be betting onImplied upside of 302% is too large to trust. At this size the likeliest explanations are a data error or earnings that are about to fall, not an opportunity the market missed. Verify EBIT and market cap against the filings before reading anything else here.
Strong case 11/12

Most of what can be measured checks out

Fallen, business intactCheap and healthy
Against it — 2 flags
Debt has risen relative to assets every year for three years.
Analysts have been cutting more than raising this quarter.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 11.7 against a Technology median of 47.1 — 75% below peers. Free cash flow yield 9.3%. Trading 61% below its all-time high set 2021-11-19.

Size of the gap

At the Technology median P/E of 56.7 instead of its current 14.8, and with earnings unchanged, the equity would be worth about 283% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 63% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 7/9 — accounts improving year on year
  • revenue compounding at 11% over three years
  • net debt 0.0x EBITDA — balance sheet not forcing anything
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus hold from 34 analysts, mean target 269.61 USD, 2% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 70% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 252 days old
HARL.TA Tel Aviv
Harel Insurance Investments & Financial Services Ltd
Financial Services
Price
174.40 ILS
P/E
12.0
EV/EBIT
5.6
Worst fall
69.5%
Volatility
34.9%
Below high
15.3%
+70% / -21% 3.3:1

Up: at the Financial Services median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 7/8

Most of what can be measured checks out

Cheap and healthy
Against it — 1 flag
Debt has risen relative to assets every year for three years.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

The 8 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 5.6 against a Financial Services median of 8.0 — 29% below peers. Free cash flow yield 16.4%.

Size of the gap

At the Financial Services median EV/EBIT of 8.0 instead of its current 5.6, and with earnings unchanged, the equity would be worth about 35% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 54% — still earning above a plausible cost of capital
  • free cash flow positive
  • revenue compounding at 31% over three years
  • operating margin 19%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Only 1 analyst estimate(s) — thin coverage
  • Data warnings on this row — see caveats below
What the sell side says

mean target 150.00 ILS, 14% below the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Trading 14% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
BMY NYSE
Bristol-Myers Squibb Company
Healthcare
Price
64.72 USD
P/E
18.7
EV/EBIT
15.0
Worst fall
70.6%
Volatility
26.4%
Below high
5.8%
+60% / -32% 1.9:1

Up: at the Healthcare median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 10/12

Most of what can be measured checks out

Growing, not yet priced for it
The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 15.0 against a Healthcare median of 22.1 — 32% below peers. Free cash flow yield 7.6%.

Size of the gap

At the Healthcare median EV/EBIT of 22.1 instead of its current 15.0, and with earnings unchanged, the equity would be worth about 60% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 15% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 9/9 — accounts improving year on year
  • operating margin 23%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus buy from 24 analysts, mean target 66.21 USD, 2% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 60% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
PGR NYSE
The Progressive Corporation
Financial Services
Price
215.33 USD
P/E
11.1
EV/EBIT
7.7
Worst fall
71.1%
Volatility
28.4%
Below high
21.2%
+29% / -22% 1.3:1

Up: at the Financial Services median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 8/9

Most of what can be measured checks out

Cheap and healthy
The 9 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

P/E of 11.1 against a Financial Services median of 13.2 — 16% below peers. Free cash flow yield 15.3%.

Size of the gap

At the Financial Services median EV/EBIT of 8.0 instead of its current 7.7, and with earnings unchanged, the equity would be worth about 2% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 66% — still earning above a plausible cost of capital
  • free cash flow positive
  • revenue compounding at 21% over three years
  • operating margin 17%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus hold from 21 analysts, mean target 229.78 USD, 7% above the current price. Revisions over the last quarter are balanced.

Targets spread 48% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
INTU NASDAQ
Intuit Inc.
Technology
Price
325.25 USD
P/E
23.0
EV/EBIT
17.9
Worst fall
75.3%
Volatility
45.7%
Below high
59.3%
+167% / -26% over 5:1

Up: at the Technology median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on current earnings estimates, and analysts have been cutting them. The bet is that the cuts are finished.
Strong case 10/12

Most of what can be measured checks out

Fallen, business intact
Against it — 1 flag
Analysts have been cutting more than raising this quarter.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 17.9 against a Technology median of 47.1 — 62% below peers. Free cash flow yield 6.7%. Trading 59% below its all-time high set 2025-07-30.

Size of the gap

At the Technology median EV/EBIT of 47.1 instead of its current 17.9, and with earnings unchanged, the equity would be worth about 167% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 19% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 9/9 — accounts improving year on year
  • revenue compounding at 14% over three years
  • net debt 0.4x EBITDA — balance sheet not forcing anything
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus buy from 33 analysts, mean target 454.65 USD, 40% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 148% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 374 days old
CLIS.TA Tel Aviv
Clal Insurance Enterprises Holdings Ltd.
Financial Services
Price
226.70 ILS
P/E
8.1
EV/EBIT
6.4
Worst fall
86.3%
Volatility
39.7%
Below high
23.5%
+88% / -37% 2.4:1

Up: at the Financial Services median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 7/8

Most of what can be measured checks out

Cheap and healthy
The 8 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 6.4 against a Financial Services median of 8.0 — 19% below peers. Free cash flow yield 7.7%.

Size of the gap

At the Financial Services median EV/EBIT of 8.0 instead of its current 6.4, and with earnings unchanged, the equity would be worth about 35% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 14% — still earning above a plausible cost of capital
  • free cash flow positive
  • revenue compounding at 46% over three years
  • operating margin 19%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Only 1 analyst estimate(s) — thin coverage
  • Data warnings on this row — see caveats below
What the sell side says

mean target 290.00 ILS, 28% above the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
ACN NYSE
Accenture plc
Technology
Price
175.72 USD
P/E
14.0
EV/EBIT
9.6
Worst fall
68.2%
Volatility
30.4%
Below high
54.5%

No two-sided case — see the bet below.

What you'd be betting onImplied upside of 378% is too large to trust. At this size the likeliest explanations are a data error or earnings that are about to fall, not an opportunity the market missed. Verify EBIT and market cap against the filings before reading anything else here.
Strong case 10/12

Most of what can be measured checks out

Fallen, business intact
Against it — 2 flags
Debt has risen relative to assets every year for three years.
Analysts have been cutting more than raising this quarter.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 9.6 against a Technology median of 47.1 — 80% below peers. Free cash flow yield 10.4%. Trading 55% below its all-time high set 2025-02-05.

Size of the gap

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

Business still intact
  • ROIC 30% — still earning above a plausible cost of capital
  • free cash flow positive
  • net debt -0.3x EBITDA — balance sheet not forcing anything
  • Altman Z 4.1 — outside the distress zone
  • operating margin 16%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus buy from 25 analysts, mean target 178.89 USD, 2% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 81% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 343 days old
MTRX.TA Tel Aviv
Matrix IT Ltd.
Technology
Price
88.00 ILS
P/E
26.5
EV/EBIT
16.7
Worst fall
63.6%
Volatility
33.6%
Below high
41.4%
+186% / -26% over 5:1

Up: at the Technology median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 9/11

Most of what can be measured checks out

Fallen, business intact
The 11 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 16.7 against a Technology median of 47.1 — 64% below peers. Free cash flow yield 9.6%. Trading 41% below its all-time high set 2026-01-14.

Size of the gap

At the Technology median EV/EBIT of 47.1 instead of its current 16.7, and with earnings unchanged, the equity would be worth about 186% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 28% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 9/9 — accounts improving year on year
  • revenue compounding at 10% over three years
  • net debt 0.3x EBITDA — balance sheet not forcing anything
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Only 1 analyst estimate(s) — thin coverage
  • Data warnings on this row — see caveats below
What the sell side says

mean target 120.00 ILS, 36% above the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
NEM NYSE
Newmont Corporation
Basic Materials
Price
112.98 USD
P/E
16.8
EV/EBIT
10.1
Worst fall
77.7%
Volatility
39.8%
Below high
14.0%
+161% / -24% over 5:1

Up: at the Basic Materials median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 12/12

Most of what can be measured checks out

Cheap and healthy
The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 10.1 against a Basic Materials median of 26.6 — 62% below peers. Free cash flow yield 6.3%.

Size of the gap

At the Basic Materials median EV/EBIT of 26.6 instead of its current 10.1, and with earnings unchanged, the equity would be worth about 161% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 22% — still earning above a plausible cost of capital
  • free cash flow positive
  • Piotroski F-Score 9/9 — accounts improving year on year
  • revenue compounding at 24% over three years
  • net debt -0.2x EBITDA — balance sheet not forcing anything
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus buy from 21 analysts, mean target 130.36 USD, 15% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 77% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
ISRG NASDAQ
Intuitive Surgical, Inc.
Healthcare
Price
378.81 USD
P/E
47.5
EV/EBIT
Worst fall
82.3%
Volatility
48.1%
Below high
37.9%

No two-sided case — see the bet below.

What you'd be betting onNot enough peer data to price a downside — treat the upside figure as unbounded on the wrong side.
Strong case 6/7

Most of what can be measured checks out

Fallen, business intact
Against it — 1 flag
Analysts have been cutting more than raising this quarter.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

The 7 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

Trading 38% below its all-time high set 2025-01-22.

Size of the gap

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

Business still intact
  • free cash flow positive
  • Piotroski F-Score 7/9 — accounts improving year on year
  • revenue compounding at 17% over three years
  • Altman Z 32.8 — outside the distress zone
  • operating margin 29%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus buy from 29 analysts, mean target 477.25 USD, 26% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 76% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 221 days old
QCOM NASDAQ
QUALCOMM Incorporated
Technology
Price
167.86 USD
P/E
31.8
EV/EBIT
13.6
Worst fall
86.8%
Volatility
48.5%
Below high
32.9%
+253% / -26% over 5:1

Up: at the Technology median multiple. Down: EBIT falling 25% at today's multiple. Both are arithmetic on today's earnings — neither is a probability.

What you'd be betting onThe case rests on earnings holding and the multiple normalising. The question the numbers cannot answer is why the market disagrees — that is in the filings and the news.
Strong case 11/12

Most of what can be measured checks out

Cheap and healthy
The 12 criteria

Valuation

  • Cheaper than sector peers
  • EV/EBIT under 15
  • Free cash flow yield over 5%

Quality

  • ROIC over 10%
  • Operating margin over 10%
  • Gross profit over 20% of assets
  • Piotroski F-Score 7 or better

Balance sheet

  • Net debt under 2.5x EBITDA
  • Altman Z above 2.6
  • Free cash flow positive

Direction

  • Revenue growing over three years
  • Analyst revisions not negative
Why it's cheap

EV/EBIT of 13.6 against a Technology median of 47.1 — 71% below peers. Free cash flow yield 7.1%. Trading 33% below its all-time high set 2026-05-29.

Size of the gap

At the Technology median EV/EBIT of 47.1 instead of its current 13.6, and with earnings unchanged, the equity would be worth about 253% more. That is the size of the gap, not a forecast that it closes.

Business still intact
  • ROIC 23% — still earning above a plausible cost of capital
  • free cash flow positive
  • net debt 0.3x EBITDA — balance sheet not forcing anything
  • Altman Z 6.4 — outside the distress zone
  • operating margin 30%
What this can't see
  • Why the market is discounting this — needs the filings and the news
  • Whether earnings are about to fall and justify the current multiple
  • Data warnings on this row — see caveats below
What the sell side says

Consensus hold from 30 analysts, mean target 194.77 USD, 16% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 154% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Data caveats
  • latest statements are 313 days old